Pharmacological or genetic inhibition of CatB decreases Aβ levels and improves the memory function in mouse models of Alzheimer's disease (Hook, Kindy, Reinheckel, Peters, & Hook, 2009; Kindy et al., 2012). This evidence concerns the gene TYRP1 and early-onset autosomal dominant Alzheimer disease.